Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The firm focuses on astaxanthin, a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. Its product platform includes pharmaceutical candidates CDX-101 and CDX-301, and dietary supplement, ZanthoSyn. The company was founded on February 7, 2014 and is headquartered in Honolulu, HI.